Full Press Release Details
Eidos Therapeutics Announces Positive Phase 2 Data For AG10 In Symptomatic Patients With Mutant Or Wild-type TTR Amyloid Cardiomyopathy.
BBIO
Eidos Therapeutics Announces Positive Phase 2 Data For AG10 In Symptomatic Patients With Mutant Or Wild-type TTR Amyloid Cardiomyopathy
Key Takeaway: Eidos Therapeutics Announces Positive Phase 2 Data For AG10 In Symptomatic Patients With Mutant Or Wild-type TTR Amyloid Cardiomyopathy